Despite having promising activities in cell culture, most of the current SHP2 PROTACs did not exhibit in vivo efficacies, although D26 did show modest anticancer activities (<20% tumor growth inhibition) as a single agent in a xenograft mice model [27]. This evidence concerns the gene PTPN11 and neoplasm.